Tags

Type your tag names separated by a space and hit enter

[Gerhard Henrik Armauer Hansen--still of current interest].
Tidsskr Nor Laegeforen. 1992 Dec 10; 112(30):3795-8.TN

Abstract

Armauer Hansen described his first observation of Mycobacterium leprae on 28 February 1873 in detail. His discovery of the leprosy bacillus was the result of a logical process in which distinct stages can be clearly seen. The first step was clinical, and established criteria for leprosy as "a specific disease". The second stage was epidemiological. Contrary to the main view favouring a genetic basis, these observations convinced him of the infectious nature of the disease. The third stage was the search for the bacillus. His basic observations were reproduced, as documented. Armauer Hansen afterwards tried to fulfill Koch's postulates, in order to prove that the bacillus was the causative agent of leprosy. His second main contribution is the work on leprosy control, emphasizing isolation to contain the infection. The subsequent decline of leprosy in Norway differs from the trend in many developing countries, where leprosy has remained an important public health problem. In recent years Norwegian medical research has made significant contributions to leprosy research, in the field of epidemiology in Bergen, and through immunological studies of the disease originating from the Armauer Hansen Research Institute in Addis Ababa, Ethiopia.

Authors+Show Affiliations

Institutt for generell og revmatologisk immunologi, Oslo.

Pub Type(s)

Biography
Historical Article
Journal Article
Portrait

Language

nor

PubMed ID

1485294

Citation

Harboe, M. "[Gerhard Henrik Armauer Hansen--still of Current Interest]." Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke, vol. 112, no. 30, 1992, pp. 3795-8.
Harboe M. [Gerhard Henrik Armauer Hansen--still of current interest]. Tidsskr Nor Laegeforen. 1992;112(30):3795-8.
Harboe, M. (1992). [Gerhard Henrik Armauer Hansen--still of current interest]. Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke, 112(30), 3795-8.
Harboe M. [Gerhard Henrik Armauer Hansen--still of Current Interest]. Tidsskr Nor Laegeforen. 1992 Dec 10;112(30):3795-8. PubMed PMID: 1485294.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Gerhard Henrik Armauer Hansen--still of current interest]. A1 - Harboe,M, PY - 1992/12/10/pubmed PY - 1992/12/10/medline PY - 1992/12/10/entrez SP - 3795 EP - 8 JF - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke JO - Tidsskr Nor Laegeforen VL - 112 IS - 30 N2 - Armauer Hansen described his first observation of Mycobacterium leprae on 28 February 1873 in detail. His discovery of the leprosy bacillus was the result of a logical process in which distinct stages can be clearly seen. The first step was clinical, and established criteria for leprosy as "a specific disease". The second stage was epidemiological. Contrary to the main view favouring a genetic basis, these observations convinced him of the infectious nature of the disease. The third stage was the search for the bacillus. His basic observations were reproduced, as documented. Armauer Hansen afterwards tried to fulfill Koch's postulates, in order to prove that the bacillus was the causative agent of leprosy. His second main contribution is the work on leprosy control, emphasizing isolation to contain the infection. The subsequent decline of leprosy in Norway differs from the trend in many developing countries, where leprosy has remained an important public health problem. In recent years Norwegian medical research has made significant contributions to leprosy research, in the field of epidemiology in Bergen, and through immunological studies of the disease originating from the Armauer Hansen Research Institute in Addis Ababa, Ethiopia. SN - 0029-2001 UR - https://www.unboundmedicine.com/medline/citation/1485294/[Gerhard_Henrik_Armauer_Hansen__still_of_current_interest]_ L2 - https://medlineplus.gov/mycobacterialinfections.html DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.